Table 3.

Numbers of events, incidence rates and hazard ratios of the studied outcomes (MACEs, all-cause mortality, hypoglycemia and individual cardiovascular outcomes) (as-treated analysis).

	No. of events	Median (IQR) time to event (years)	Follow-up time (person-years)	Incidence rate (per 1000 person-years)	Hazard ratio
MACEs
Basal insulin	36	0.40 (0.14–0.96)	4,035	8.92	Reference
TZDs	103	0.35 (0.16–0.90)	9,513	10.83	1.24 (0.85–1.82)
Basal insulin	37	0.38 (0.14–0.80)	3,984	9.29	Reference
DPP-4is	103	0.44 (0.19–0.95)	11,085	9.29	1.06 (0.73–1.54)
All-cause mortality
Basal insulin	46	0.37 (0.25–0.73)	4,043	11.38	Reference
TZDs	61	0.57 (0.25–1.22)	9,543	6.39	0.55 (0.38–0.81)
Basal insulin	45	0.38 (0.25–0.73)	3,992	11.27	Reference
DPP-4is	69	0.52 (0.30–1.02)	11,140	6.19	0.56 (0.39–0.82)
Hypoglycemia
Basal insulin	49	0.19 (0.08–0.72)	3,527	13.89	Reference
TZDs	117	0.42 (0.19–0.94)	8,532	13.71	1.01 (0.72–1.41)
Basal insulin	49	0.19 (0.09–0.72)	3,480	14.08	Reference
DPP-4is	101	0.37 (0.12–1.10)	10,091	10.01	0.78 (0.55–1.10)
Myocardial infarction
Basal insulin	10	0.55 (0.16–1.16)	4,040	2.48	Reference
TZDs	27	0.38 (0.15–1.38)	9,536	2.83	1.16 (0.56–2.40)
Basal insulin	10	0.55 (0.16–1.16)	3,989	2.51	Reference
DPP-4is	20	0.37 (0.22–0.69)	11,131	1.80	0.75 (0.35–1.62)
Ischemic stroke
Basal insulin	22	0.38 (0.13–1.12)	4,038	5.45	Reference
TZDs	68	0.33 (0.16–0.79)	9,520	7.14	1.35 (0.84–2.19)
Basal insulin	23	0.37 (0.13–1.12)	3,987	5.77	Reference
DPP-4is	73	0.45 (0.17–1.07)	11,098	6.58	1.21 (0.76–1.94)
Cardiovascular death
Basal insulin	5	0.72 (0.21–0.76)	4,043	1.24	Reference
TZDs	9	0.39 (0.28–0.80)	9,543	0.94	0.77 (0.26–2.30)
Basal insulin	5	0.72 (0.21–0.76)	3,992	1.25	Reference
DPP-4is	13	0.38 (0.30–0.86)	11,140	1.17	1.03 (0.36–2.92)

Abbreviations: DPP-4is, dipeptidylpeptidase-4 inhibitors; IQR, interquartile range; MACEs, major adverse cardiovascular events; TZDs, thiazolidinediones.